Press Releases - Boehringer Ingelheim
WEBFind the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim reports strong growth in 2023 and …
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
First half of 2024: Boehringer Ingelheim progresses
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
First half of 2023: Boehringer Ingelheim sees strong growth and ...
WEBAug 1, 2023 · INGELHEIM, Germany-- (BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health...
Topline results from Boehringer's Phase III IPF ... - Boehringer Ingelheim
WEB6 days ago · Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug ...
First half of 2024: Boehringer Ingelheim progresses pipeline at …
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
Boehringer Ingelheim GmbH - The New York Times
WEBHikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. By Chad Bray.
Boehringer Ingelheim and IBM Collaborate to Advance …
WEBNov 28, 2023 · Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.
Boehringer Ingelheim Faces Second Hung Jury in Chicago Zantac …
WEB4 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
WEB6 days ago · Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...